GSK slams ACCC’s ‘onerous’ compliance program in Voltaren case
Bird & Bird 2018-08-01 9:01 pm By Miklos Bolza | Sydney
Please login to bookmark Close

The final day of trial in the ACCC’s case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as ‘onerous’ a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant ‘inherited’ from Novartis.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au